In addition to these enhanced workstations at AAD, Cynosure (Booth # 3707) is featuring its new Cellulaze ™ Workstation, the world's only FDA-cleared, minimally invasive aesthetic device for cellulite reduction. Cellulaze reduces cellulite in just one treatment by restoring the normal structure of the skin and underlying connective tissue. It is designed to diminish the lumpy pockets of fat, release the areas of skin depression typifying cellulite and increase the elasticity and thickness of the skin.About Cynosure, Inc. Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis, reduce the appearance of cellulite and treat Onychomycosis. Cynosure's products include a broad range of laser- and other light-based energy sources, including Alexandrite, pulse dye, Q-switched, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com. Forward-Looking StatementsAny statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the Apogee+, Elite+ and Cellulaze, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the global economy and lending environment and their effects on the aesthetic laser industry, Cynosure's history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release. Contact: Scott SolomonVice PresidentSharon Merrill Associates, Inc.617.542.5300 email@example.com SOURCE Cynosure, Inc.